ID: ALA2206826

Max Phase: Preclinical

Molecular Formula: C7H16N2O3

Molecular Weight: 176.22

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H](O)NC[C@H]1NC[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C7H16N2O3/c1-4(10)8-2-5-7(12)6(11)3-9-5/h4-12H,2-3H2,1H3/t4-,5-,6+,7-/m1/s1

Standard InChI Key:  ILPLXBQAXZPQTP-MVIOUDGNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 176.22

Molecular Weight (Monoisotopic): 176.1161

AlogP: -2.39

#Rotatable Bonds: 3

Polar Surface Area: 84.75

Molecular Species: BASE

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.30

CX Basic pKa: 8.88

CX LogP: -2.28

CX LogD: -3.77

Aromatic Rings: 0

Heavy Atoms: 12

QED Weighted: 0.31

Np Likeness Score: 1.58

References

1. Popowycz F, Gerber-Lemaire S, Demange R, Rodriguez-García E, Asenjo AT, Robina I, Vogel P..  (2001)  Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors.,  11  (18): [PMID:11549453] [10.1016/s0960-894x(01)00477-2]

2. Moorthy NS, Brás NF, Ramos MJ, Fernandes PA..  (2012)  Virtual screening and QSAR study of some pyrrolidine derivatives as α-mannosidase inhibitors for binding feature analysis.,  20  (24): [PMID:23151473] [10.1016/j.bmc.2012.10.011]

Source

Source(1):

• Scientific Literature